Olfr806 is a member of the olfactory receptor (OR) family, belonging to the category of G protein-coupled receptors (GPCRs), which are integral to the sense of smell. Olfactory receptors, including Olfr806, play a vital role in detecting odorant molecules, triggering the olfactory signal transduction pathway. The typical mode of activation for these receptors involves the binding of specific odorant molecules, which induces conformational changes in the receptor. These changes facilitate interaction with G proteins, leading to a series of intracellular signaling events culminating in the perception of smell. The specific ligands and full range of physiological functions of Olfr806, as with many ORs, are not entirely elucidated, reflecting the diversity and specificity of olfactory receptors. The activation mechanisms of Olfr806, akin to other GPCRs, are modulated by various cellular factors. A key regulatory pathway in GPCR function is the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP acts as a secondary messenger, playing a crucial role in numerous cellular functions, including GPCR signaling. Adenylate cyclase, which converts ATP into cAMP in response to stimuli, regulates the production of cAMP. Accumulation of cAMP activates protein kinase A (PKA), resulting in phosphorylation of target proteins, including GPCRs. This phosphorylation can alter the receptor's sensitivity and responsiveness to ligands. Additionally, cAMP can modulate other signaling pathways that intersect with GPCR signaling, thus influencing the activity of receptors like Olfr806.
Phosphodiesterases (PDEs), which break down cAMP, are vital in maintaining its intracellular levels. Inhibiting PDEs leads to increased cAMP within the cell, indirectly affecting GPCR signaling. This increase in cAMP, due to PDE inhibition, can indirectly modulate the activity of Olfr806 through various mechanisms, such as changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Moreover, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly affect the activity of Olfr806. These interactions illustrate the complexity of GPCR regulation and underscore the potential of various chemical compounds to modulate the activity of receptors like Olfr806 indirectly. In conclusion, studying the activation of Olfr806 is critical for understanding the olfactory system and the broader role of GPCRs in sensory perception and physiological processes. The complex interplay between different cellular components and signaling molecules, coupled with the potential for modulation by external compounds, highlights the complexity and significance of these receptors in sensory perception and cellular communication.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, raises intracellular cAMP through adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr806 signaling pathways, enhancing receptor activation and signal transduction. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels, potentially influencing Olfr806 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors, increasing cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr806 activation, potentially enhancing its activity through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, increases cAMP levels. Elevated cAMP may enhance Olfr806 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a selective PDE3 inhibitor, raises intracellular cAMP, potentially influencing Olfr806 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol, a β2-adrenergic agonist, increases cAMP levels via adenylate cyclase activation. This increase might boost Olfr806 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr806 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr806 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr806 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy. | ||||||